First Read: China Medtech "Diagnostics Services Price Items Guideline..."

Research evidence excerpt

First Read: China Medtech "Diagnostics Services Price Items Guideline..."

Global Research

1 July 2026ab

First Read

EquitiesChina Medtech

Diagnostics Services Price Items Guideline China

released for Round 2 comment solicitation Healthcare

Jun Deng

Analyst

jun.deng@ubs.com

What happened? +852-3712 2103

On 30 June 2026, China's NHSA released an updated draft of the Diagnostics Services Emma Ma, CFA

Price Items Guideline to its provincial branches for Round 2 comment solicitation by 8 Associate

July 2026. Recall that NHSA issued the first draft for comment solicitation by in March S1460124070003

2026 (note). We think the rare move for NHSA to initiate another round of comment emma-mc.ma@ubs.com

solicitation might suggest the policy's importance to hospitals/ manufacturers and +86-21-3866 8981

considerable feedback received in the last few months. In terms of the new draft, we Chen Chen, PhD

didn't see many material changes from the previous version. Meanwhile, the slight delay Analyst

in policy implementation might lead to above-expectation Q326 China IVD revenue for S1460520100001

some companies, in our view. We are scheduled to speak with New Industries, one of chen-zb.chen@ubs.com

the domestic IVD leaders, at 2pm HKT on 3 July (Friday) in our China Healthcare +86-10-5832 8201

Virtual Tour, please register here for the event (mandarin only). Tomoko Yoshihara

What is different in the updated guideline? tomoko.yoshihara@ubs.com

+81-3-5208 6212

In the new draft, two principles from last version remain intact: 1) the same price for the

same test item regardless of test methodologies, and 2) reagent cost should be covered Graham Doyle

by the price items without incurring additional charges. Key changes in this version: Analyst

graham.doyle@ubs.com